Last reviewed · How we verify
Amlodipine low
Amlodipine is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.
Amlodipine is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Amlodipine low |
|---|---|
| Also known as | Amlodipine low placebo |
| Sponsor | Addpharma Inc. |
| Drug class | Calcium channel blocker |
| Target | L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Amlodipine binds to L-type calcium channels in smooth muscle cells, reducing the influx of calcium ions and subsequent muscle contraction. This leads to vasodilation and a decrease in peripheral resistance, resulting in lowered blood pressure.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Edema
- Dizziness
- Headache
- Fatigue
- Nausea
Key clinical trials
- Role of Amlodipine in Reduction of CIN (EARLY_PHASE1)
- Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension (PHASE2)
- Correlates and Control of Blood Pressure Variability (PHASE1)
- Efficacy and Safety of SPC1001 in Patients With Essential Hypertension (PHASE2)
- Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (PHASE2)
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine low CI brief — competitive landscape report
- Amlodipine low updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI